Analyst Ratings For G1 Therapeutics
Portfolio Pulse from Benzinga Insights
In the last three months, 8 analysts have published ratings on G1 Therapeutics (NASDAQ:GTHX), all of which are bullish. The average 12-month price target is $10.88, with a high of $12.00 and a low of $9.00. The company's financial health shows mixed results, with strong revenue growth but challenges in debt management and return on equity.
June 13, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
G1 Therapeutics has received 8 bullish ratings from analysts in the last three months, with an average price target of $10.88. The company's financial health shows strong revenue growth but challenges in debt management and return on equity.
The unanimous bullish ratings from analysts and the upward trend in price targets indicate positive sentiment towards G1 Therapeutics. However, the company's financial health shows mixed results, with strong revenue growth but challenges in debt management and return on equity. This suggests cautious optimism for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100